Objective To integrate the mechanism of Qinge pill in the treatment of postmenopausal osteoporosis (PMO) with network pharmacology approach. Methods The main active components of Qinge pill were obtained by using TCMSP, ETCM, and SymMap database and Literature retrieval. The component target prediction was performed using Swiss Target Prediction. PMO-related targets were obtained through the GeneCards database, OMIM database, and DisGeNET database, and the intersections with the drug targets was caught to obtain the potential therapeutic targets of Qinge pill for PMO. Cytoscape software was used to construct the network diagram of TCM, active ingredient, and intersection target of Qinge pill for PMO treatment. The protein–protein interaction network was analyzed using the String database and Cytoscape software. The key targets were selected according to the degree value. The gene ontology function and KEGG pathway enrichment analysis were performed on the key targets using DAVID database to explore the mechanism of Qinge pill in the treatment of PMO. Results 40 active ingredients were selected, including delphinidin, quercetin, and kaempferol, etc. 178 potential targets of Qinge pill in the treatment of PMO were found. By analyzing the protein interaction network of intersection targets, 68 key targets were obtained, mainly including MAPK1, AKT1, PIK3CA, and JAK2, etc. The GO and KEGG enrichment analysis of key target genes showed that the key targets mainly played roles in plasma membrane, membrane raft, nucleus, and other positions, and carried out the positive regulation of nitric oxide biosynthesis, signal transduction, protein phosphorylation, and other biological processes. and functioned in kinase activity, protein binding, and protein kinases binding. Moreover, the key targets regulated PMO through cancer pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway, and estrogen, prolactin, and thyroid hormone signaling pathways. Conclusion The active components in Qinge pills, such as delphinidin, quercetin, and kaempferol, may regulate bone metabolism and treat PMO by participating in PI3K-Akt, HIF-1, estrogen and prolactin signaling pathways and acting on MAPK1, AKT1, PIK3CA, and JAK2 gene targets. |